GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Infusions Ltd (DHA:ORIONINFU) » Definitions » Beneish M-Score

Orion Infusions (DHA:ORIONINFU) Beneish M-Score : -2.76 (As of May. 13, 2024)


View and export this data going back to . Start your Free Trial

What is Orion Infusions Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.76 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Orion Infusions's Beneish M-Score or its related term are showing as below:

DHA:ORIONINFU' s Beneish M-Score Range Over the Past 10 Years
Min: -3.1   Med: -2.45   Max: 9.62
Current: -2.76

During the past 13 years, the highest Beneish M-Score of Orion Infusions was 9.62. The lowest was -3.10. And the median was -2.45.


Orion Infusions Beneish M-Score Historical Data

The historical data trend for Orion Infusions's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orion Infusions Beneish M-Score Chart

Orion Infusions Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.69 -2.73 -2.71 -2.49 -2.43

Orion Infusions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.30 -2.34 -2.43 -2.78 -2.76

Competitive Comparison of Orion Infusions's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orion Infusions's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Orion Infusions's Beneish M-Score falls into.



Orion Infusions Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Orion Infusions for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8967+0.528 * 1.0258+0.404 * 0.9531+0.892 * 1.0023+0.115 * 0.4269
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1239+4.679 * -0.02132-0.327 * 0.9798
=-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was BDT135.2 Mil.
Revenue was 202.732 + 235.854 + 202.881 + 183.278 = BDT824.7 Mil.
Gross Profit was 81.138 + 92.243 + 85.68 + 73.061 = BDT332.1 Mil.
Total Current Assets was BDT433.5 Mil.
Total Assets was BDT828.7 Mil.
Property, Plant and Equipment(Net PPE) was BDT372.0 Mil.
Depreciation, Depletion and Amortization(DDA) was BDT27.1 Mil.
Selling, General, & Admin. Expense(SGA) was BDT-25.6 Mil.
Total Current Liabilities was BDT504.4 Mil.
Long-Term Debt & Capital Lease Obligation was BDT9.0 Mil.
Net Income was 8.307 + 13.392 + 13.14 + 7.812 = BDT42.7 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = BDT0.0 Mil.
Cash Flow from Operations was 6.089 + 1.702 + 43.1 + 9.429 = BDT60.3 Mil.
Total Receivables was BDT150.4 Mil.
Revenue was 199.052 + 224.941 + 217.421 + 181.406 = BDT822.8 Mil.
Gross Profit was 78.204 + 90.476 + 96.024 + 75.178 = BDT339.9 Mil.
Total Current Assets was BDT440.8 Mil.
Total Assets was BDT794.2 Mil.
Property, Plant and Equipment(Net PPE) was BDT330.0 Mil.
Depreciation, Depletion and Amortization(DDA) was BDT9.9 Mil.
Selling, General, & Admin. Expense(SGA) was BDT-22.7 Mil.
Total Current Liabilities was BDT480.5 Mil.
Long-Term Debt & Capital Lease Obligation was BDT21.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(135.18 / 824.745) / (150.408 / 822.82)
=0.163905 / 0.182796
=0.8967

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(339.882 / 822.82) / (332.122 / 824.745)
=0.41307 / 0.402697
=1.0258

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (433.524 + 372.027) / 828.746) / (1 - (440.834 + 330.014) / 794.168)
=0.027988 / 0.029364
=0.9531

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=824.745 / 822.82
=1.0023

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9.854 / (9.854 + 330.014)) / (27.107 / (27.107 + 372.027))
=0.028994 / 0.067915
=0.4269

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(-25.627 / 824.745) / (-22.749 / 822.82)
=-0.031073 / -0.027648
=1.1239

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((8.978 + 504.438) / 828.746) / ((21.584 + 480.531) / 794.168)
=0.619509 / 0.632253
=0.9798

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(42.651 - 0 - 60.32) / 828.746
=-0.02132

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Orion Infusions has a M-score of -2.76 suggests that the company is unlikely to be a manipulator.


Orion Infusions Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Orion Infusions's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Orion Infusions (DHA:ORIONINFU) Business Description

Traded in Other Exchanges
N/A
Address
Tejgaon Industrial Area, No. 153-154, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company. It produces various types of intravenous fluids, rehydration solutions, electrolyte solutions, antimicrobial products, and other pharmaceutical products in Bangladesh. The products of the company include Dextrolac, Dextropac, Dextrosal, Dianak, Electro dex, fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the company is also involved in activities related to cosmetics and toiletries, infrastructure development, real estate and construction, power, agro products, hospitality, textiles and garments, and aviation management sectors. Geographically, it operates in Bangladesh.

Orion Infusions (DHA:ORIONINFU) Headlines

No Headlines